GlassScriptPhysician profile
Corazon B Cajulis
NPI 1467757468
$4,024.54
in general payments reported to CMS, 2019-2025
29 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $741 · 2023: $755 · 2024: $733 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.96 |
| Education | $277.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $528.85 | 2022-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $497.15 | 2022-2025 | |
| Stemline Therapeutics INC. | $371.09 | 2024-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $347.72 | 2021-2025 | Keytruda, Dificid, Prevymis |
| Astellas Pharma US INC | $269.29 | 2023-2025 | Vyloy, Xtandi, Xospata |
| Incyte Corporation | $243.00 | 2025 | Pemazyre, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $186.08 | 2021-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $171.14 | 2022-2025 | Calquence, Tagrisso |
| Amgen INC. | $143.02 | 2021-2025 | Imdelltra (Amg757) |
| Immunocore Limited | $128.06 | 2023-2025 | Kimmtrak |
| Karyopharm Therapeutics INC. | $123.23 | 2022 | |
| Genzyme Corporation | $122.88 | 2021 | |
| Abbvie INC. | $113.51 | 2023 | |
| Daiichi Sankyo INC. | $102.11 | 2022-2025 | Enhertu |
| Eisai INC. | $99.69 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $97.64 | 2022-2023 | Pomalyst |
| Emd Serono, INC. | $80.26 | 2022-2023 | Bavencio, Tepmetko |
| Jazz Pharmaceuticals INC. | $78.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.72 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $40.29 | 2024-2025 | Ultomiris |
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Array Biopharma INC | $27.48 | 2024 | Braftovi, Mektovi |
| Tersera Therapeutics LLC | $25.86 | 2025 | Xermelo |
| Legend Biotech USA INC. | $24.59 | 2025 | Carvykti |
| Foundation Medicine, INC. | $23.82 | 2023 | Foundationone Liquid Cdx |
| Dova Pharmaceuticals | $22.64 | 2021 | |
| Rigel Pharmaceuticals, INC. | $21.87 | 2023 | Tavalisse, Rezlidhia |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Janssen Biotech, INC. | $19.97 | 2024 | Tecvayli, Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Cajulis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.